



Published in final edited form as:

*Yeast*. 2021 December ; 38(12): 615–624. doi:10.1002/yea.3670.

## Absence of *MMF1* disrupts heme biosynthesis by targeting Hem1p in *Saccharomyces cerevisiae*

Gregory H. Whitaker, Dustin C. Ernst<sup>a</sup>, Diana M. Downs<sup>\*</sup>

Department of Microbiology, University of Georgia, Athens, GA 30602-2605

### Abstract

The RidA subfamily of the Rid (YjgF/YER057c/UK114) superfamily of proteins is broadly distributed and found in all domains of life. RidA proteins are enamine/imine deaminases. In the organisms that have been investigated, lack of RidA results in accumulation of the reactive enamine species 2-aminoacrylate (2AA) and/or its derivative imine 2-iminopropanoate (2IP). The accumulated enamine/imine species can damage specific pyridoxal phosphate (PLP)-dependent target enzymes. The metabolic imbalance resulting from the damaged enzymes is organism specific and based on metabolic network configuration. *Saccharomyces cerevisiae* encodes two RidA homologs, one localized to the cytosol and one to the mitochondria. The mitochondrial RidA homolog, Mmf1p, prevents enamine/imine stress and is important for normal growth and maintenance of mitochondrial DNA. Here we show that Mmf1p is necessary for optimal heme biosynthesis. Biochemical and/or genetic data herein support a model in which accumulation of 2AA and/or 2IP, in the absence of Mmf1p, inactivates Hem1p, a mitochondrially located PLP-dependent enzyme required for heme biosynthesis.

### Keywords

RidA; 2-aminoacrylate; heme; Hem1; Mmf1

### INTRODUCTION

The Rid protein family (YjgF/YER057c/UK114) has been split into nine subfamilies in the NCBI conserved domain database (cd00448) (Marchler-Bauer et al., 2013; Niehaus et al., 2015). Members of the RidA subfamily have enamine/imine deaminase activity and are found in all domains of life (Digiovanni et al., 2020; ElRamlawy et al., 2016; D. C. Ernst & Downs, 2018; J. Irons, Hodge-Hanson, & Downs, 2018; J. Irons, Sacher, Szymanski, & Downs, 2019; Lambrecht, Schmitz, & Downs, 2013; Martínez-Chavarría et al., 2020; Niehaus et al., 2015). 2-aminoacrylate (2AA) is a reactive enamine that is generated by pyridoxal 5'-phosphate (PLP)-dependent enzymes as an obligatory intermediate in some reactions, specifically the breakdown of serine. Like other enamines, 2AA rapidly tautomerizes to its imine, 2-iminopropanoate (2IP). The imine is subsequently hydrolyzed

<sup>\*</sup>Correspondence: Dr. Diana Downs, Department of Microbiology, University of Georgia, Athens, GA, USA, dmdowns@uga.edu.

<sup>a</sup>Current address: Enlaza Therapeutics, Inc., La Jolla CA 92037

### CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest with the contents of this article.

to form a stable keto acid, which in the case of 2IP is pyruvate. 2AA can react with and irreversibly damage enzymes by forming an adduct with the PLP-enzyme complex (Borchert, Ernst, & Downs, 2019; Esaki & Walsh, 1986; Walsh, 1982). In strains lacking *RidA*, the accumulation of 2AA/2IP generates endogenous metabolic stress that has diverse phenotypic manifestations characteristic of the organism involved (J. L. Irons, Hodge-Hanson, & Downs, 2020). The inability to easily distinguish between enamine/imine molecules, or control their tautomerization, makes it difficult to definitively assign a role for one over the other *in vivo*. However, *in vitro* mechanistic studies support the assumption that the 2AA enamine is the agent of direct damage in *ridA* mutants (Borchert et al., 2019; Lambrecht et al., 2013).

*Saccharomyces cerevisiae* encodes two *RidA* homologs, one localized to the cytoplasm (*Hmf1p*) and one to the mitochondrion (*Mmf1p*). There are no phenotypes reported for the lack of *Hmf1p*, but loss of *Mmf1p* results in growth defects and the loss of mitochondrial DNA (D. C. Ernst & Downs, 2018; Kim, Yoshikawa, & Shirahige, 2001; Oxelmark et al., 2000). Analysis of *mmf1-::KanMX(mmfl)* strains showed that the generation and accumulation of 2AA/2IP was responsible for the phenotypes of the mutant (D. C. Ernst & Downs, 2018), closely mirroring the paradigm identified and rigorously characterized in *Salmonella enterica* (Borchert et al., 2019; D. C. Ernst & Downs, 2018; J. L. Irons et al., 2020; Lambrecht et al., 2013). In the case of *S. enterica*, serine/threonine dehydratase (E.C. 4.3.1.19, *IlvA*) is the primary generator of 2AA/2IP from endogenous L-serine. While 2AA/2IP can be hydrolyzed nonenzymatically to form pyruvate, low availability of free water is presumed to limit this reaction *in vivo*, and *RidA* is thus required to expedite the hydrolysis (Lambrecht et al., 2013). Phenotypes of *ridA* mutant strains of *S. enterica* are due to damage of specific PLP-dependent enzymes caused by 2AA (Downs & Ernst, 2015; Lambrecht et al., 2013).

The growth defects and loss of mtDNA in *S. cerevisiae* strains lacking *MMF1* are dependent on the activity of one or both mitochondrial serine/threonine dehydratases (*Ilv1p/Cha1p*) (D. C. Ernst & Downs, 2018) (Figure 1). The differential roles of these two enzymes allowed modulation of 2AA/2IP formation by changing growth conditions. *CHA1* encodes the catabolic serine dehydratase and is transcribed only in the presence of exogenous L-serine or L-threonine (Bornaes, Ignjatovic, Schjerling, Kielland-Brandt, & Holmberg, 1993). In contrast, the product of *ILV1* is active when no exogenous L-serine is provided and is allosterically inhibited by L-isoleucine (Ahmed, Bollon, Rogers, & Magee, 1976; D. C. Ernst & Downs, 2018). When *mmf1* yeast cells are grown under conditions in which 2AA/2IP accumulates, they grow poorly and lose mitochondrial DNA (mtDNA) at high frequency making these cells unable to respire (cytoplasmic petite) (D. C. Ernst & Downs, 2018). While the phenotypes displayed by the *mmf1* mutants are definitively caused by accumulation of 2AA and/or 2IP, the enzyme(s) targeted by 2AA to cause the metabolic perturbations are not currently known.

This study was initiated to extend our understanding of the 2AA/2IP mediated phenotypes of a *mmf1* mutant and identify targeted enzyme(s) beyond those previously reported. Results herein identified a heme deficiency in *mmf1* yeast strain that contributed to the growth defect of the mutant. Aminolevulinic acid synthase (*ALAS*, *Hem1p*, E.C. 2.3.1.37) catalyzes

the condensation of succinyl-CoA and L-glycine to form 5-aminolevulinic acid (ALA) (Hunter et al., 2012). Hem1p is a PLP-dependent enzyme located in the mitochondrion that is responsible for the first step in heme biosynthesis. Here we show that 2AA/2IP caused damage to Hem1p, which contributed to the growth defects and heme deficiency of *mmf1* yeast.

## MATERIALS AND METHODS

### Strains, media, and chemicals.

*Saccharomyces cerevisiae* strain YJF153 (MATa *ho::dsdAMX4*) was derived from an oak tree isolate (YPS163) and provided by Justin Fay (Washington University) (X. C. Li & Fay, 2017). *S. cerevisiae* strain S288c (MATa) (Mortimer & Johnston, 1986) was a gift from David Garfinkel (University of Georgia). Derivative strains are listed in Table S1.

Rich medium (YP) contained 20 g/l peptone (Fisher Scientific) and 10 g/l yeast extract. Minimal medium (S) contained 1.71 g/l yeast nitrogen base without amino acids or nitrogen (Sunrise Science; #1500–100) and ammonium sulfate (5 g/l). Either dextrose (D; 20 g/l) or glycerol (G; 30 g/l) was provided as the sole carbon source. Solid medium included 20 g/l agar (Difco). Antibiotics used for deletion marker selection were added at the following final concentrations: 400 µg/ml Geneticin (G418; Gold Biotechnology), 100 µg/ml nourseothricin sulfate (cloNAT; Gold Biotechnology). Supplements added to SD medium were: L-isoleucine (1 mM), ALA (0.24 mM) and L-glycine (1 mM).

*Escherichia coli* strain BL21-AI, which contains T7 polymerase under control of the *araBAD* promoter, was used for recombinant protein overproduction. Standard *E. coli* growth medium (LB broth) consisted of 10 g/l tryptone, 5 g/l yeast extract, and 10 g/l NaCl. Superbroth containing tryptone (32 g/l), yeast extract (20 g/l), sodium chloride (5 g/l), and sodium hydroxide (0.2 g/l) was used when high cell densities were desired for protein overproduction. Ampicillin (150 µg/ml) was added to the growth medium as needed. Reagents and chemicals were purchased from Sigma-Aldrich unless otherwise specified.

### Genetic techniques and growth methods.

Gene disruptions in *S. cerevisiae* were made following the standard gene replacement method described by Hegemann and Heck (Hegemann & Heck, 2011). Disruption cassettes were amplified using the appropriate primers and plasmid templates listed in Table S2. Purified DNA (1–5 µg) was transformed into *S. cerevisiae* by incubating cells suspended in a mixture of 33% polyethylene glycol 3350 (PEG 3350), lithium acetate (100 mM), and salmon sperm DNA (0.28 mg/ml) at 30°C for 30 min followed by 30 min of heat shock at 42°C. The transformed cells were recovered in rich medium containing dextrose (YPD) or glycerol (YPG) for 1 h at 30°C and were subsequently plated on solid YPD or YPG containing the relevant selective agent. Colonies that arose after 2 to 3 days of incubation were transferred to selective medium, and individual colonies were screened via PCR to identify the appropriate recombinants.

For growth analyses, yeast strains were revived from glycerol stocks stored at –80°C and streaked for isolation on YPG. Selection and propagation of *mmf1* mutants on YPG

prevented the loss of the mitochondrial genome that results after growth on dextrose (D. C. Ernst & Downs, 2018). Single colonies were inoculated into 5 ml cultures of SD + L-isoleucine (1 mM) and incubated at 30°C with shaking (200 rpm) overnight. Two  $\mu$ l of overnight cultures were placed into wells of a 96-well microplate. Ninety-eight  $\mu$ l of medium was added to each well and OD<sub>650</sub> measurements are used to monitor growth using a microplate reader (Biotek). Growth curves were plotted as averages and standard deviations of results from three independent cultures using GraphPad Prism 7.0.

### Molecular techniques.

Plasmids were constructed using standard molecular techniques. DNA was amplified using Q5 DNA polymerase (New England Biolabs) with primers purchased from Eton Bioscience Inc. (Research Triangle Park, NC). Plasmids were isolated using PureYield plasmid miniprep system (Promega), and PCR products were purified using QIAquick PCR purification kit (Qiagen). Restriction endonucleases used for molecular cloning were purchased from New England Biolabs. T4 ligase (Thermo Scientific) was used to ligate inserts to vectors. The plasmids and primers used are listed in Table S2. Plasmids pDM1390 and pDM1672 were provided by David Garfinkel (University of Georgia). pDM1479 was constructed by the following method: primers Hem1\_NcoI\_F and Hem1\_XbaI\_R were used to amplify *HEM1* from YJF153, omitting the mitochondrial localization sequence (9 amino acids) and introducing *NcoI* and *XbaI* restriction sites. The insert was then ligated into pET20b following restriction digest of the insert and vector and transformed into DH5 $\alpha$ .

### Protein purification.

Hem1- His<sub>6</sub> lacking the N-terminal mitochondrial localization sequence was purified from an *E. coli* strain containing pDM1479. IlvA-His<sub>6</sub> was purified from *E. coli* containing pDM1578 (pET20b-IlvA). Both proteins were purified with a similar protocol. An overnight culture of BL21 grown in 50 ml of superbroth (SB) containing ampicillin was inoculated into 6 liters of SB with ampicillin distributed in four 2.8 liter baffled Fernbach flasks. Cultures were grown at 37°C to an OD<sub>650</sub> of ~ 0.7. Arabinose (0.2%) was added to induce expression of the inserted gene, and cultures were grown at 30°C overnight (16 hours). Cells were harvested by centrifugation (15 min at 8k  $\times$  g) and resuspended in binding buffer containing potassium phosphate pH 8 (100 mM), sodium chloride (100 mM), imidazole (20 mM), PLP (10  $\mu$ M), TCEP (tris(2-carboxyethyl)phosphine; 1 mM), and glycerol (10% w/v). Lysozyme (1 mg/ml), phenylmethylsulfonyl fluoride (1 mM), and DNase (25  $\mu$ g/ml) were added, and the cell suspension was placed on ice for 1 h. Cells were mechanically lysed using a One-shot cell disruptor (once at 124 MPa). The resulting lysate was clarified by centrifugation (45 min at 48k  $\times$  g) and filtered through a membrane (0.45  $\mu$ m pore size). Filtered lysate was loaded onto HisTrap HP Ni-Sepharose columns (5 ml) and washed with five column volumes of binding buffer. Protein was eluted by increasing the concentration of imidazole in the elution buffer from 20 to 300 mM over 10 column volumes. Purified protein was concentrated by centrifugation with a 10,000-molecular-weight-cutoff filter unit (Millipore), and the buffer was replaced with potassium phosphate pH 8 (100 mM), containing PLP (10  $\mu$ M), NaCl (100 mM), and glycerol (10% w/v) using a PD-10 desalting column (GE Healthcare). Protein concentration was determined by BCA assay (Pierce) and a recovery from a typical purification was ~100mg. Protein aliquots were frozen in liquid

nitrogen and stored at 80°C. Densitometry estimated purity at >97% for Hem1p and IlvA. Mmf1p of similar purity (D. C. Ernst & Downs, 2018) was available in the laboratory.

### Purification of Hem1p expressed in *S. enterica ridA* mutants.

Hem1-His<sub>6</sub> was purified from each of two *S. enterica* strains carrying pDM1479, an isogenic pair with (DM13509) or without (DM17050) a functional RidA. Both strains contain T7 polymerase in the chromosome under control of the *araBAD* promoter. Cultures of each strain were grown overnight in LB (50 ml) containing ampicillin. For each strain, 15 ml of the overnight culture was used to inoculate each of three baffled Fernbach flasks (2.8 L) containing 1.5 liters minimal glucose medium with ampicillin (15 µg/ml), L-serine (5 mM) and L-glycine (1 mM). The resulting cultures were grown, with shaking, to an OD<sub>650</sub> of 0.3 before arabinose (0.08%) was added to induce expression. Cells were harvested by centrifugation (15 min at 7k × g) after 18 hours of growth at 30°C. The cell pellet was resuspended in 2 ml binding buffer / g cell wet weight and subjected to the lysis method described above. Binding buffer contains potassium phosphate pH 8 (50 mM), NaCl (100 mM), imidazole (40 mM), glycerol (10% w/v). Filtered lysates were loaded onto Histrap HP Ni-Sepharose columns (1 ml), washed with 10 column volumes binding buffer, and eluted with 80 mM imidazole in binding buffer. Densitometry estimated purity at 70% for the protein samples from both WT and *ridA* mutant strains (Figure S1).

### Characterization of cofactor content.

Hem1-bound cofactors were released from the protein as described previously (Flynn & Downs, 2013). KOH (30 mM final concentration) was added to purified Hem1p (50 nmol protein) and incubated at room temperature for 10 min. Protein was precipitated by addition of 10% trifluoroacetic acid to generate a visible precipitate. The precipitate was removed by centrifugation (3 min at 16k × g). The supernatant was filtered using a 0.45 µm centrifugal tube filter (Costar 8170) and the cofactors separated by high-performance liquid chromatography. Separation was performed on a Shimadzu HPLC equipped with a Luna C18 column (250 by 4.60 mm) (Phenomenex) using a 2-step isocratic method with a flow rate of 0.8 ml/min as follows: 0 to 5 min with 100% buffer A (0.06% [vol/vol] trifluoroacetic acid) and 5 to 18 min with methanol- buffer A (3:97). Between each run, the column was washed for 10 min with methanol-buffer A (60:40). The eluant was monitored at 305 nm using a photodiode array detector (Shimadzu SPD-M20A). Authentic pyridoxal 5'-phosphate (>98% pure; Sigma-Aldrich) and pyruvate/PLP served as standards. Pyruvate/PLP was synthesized as described previously (Schnackerz, Ehrlich, Giesemann, & Reed, 1979) purified by HPLC, and concentrated.

### Heme measurements.

Intracellular heme levels were measured using a protocol adapted from Hans *et. al.* (Hans, Heinze, & Wittmann, 2001). Overnight cultures of *S. cerevisiae* (2.5 ml) were used to inoculate 50 ml of SD media in a 500 ml flask and incubated with shaking (200 rpm) until an OD<sub>650</sub> of 0.4 was reached. Cells were harvested by centrifugation (3k × g for 5 min), washed with 50 ml of distilled H<sub>2</sub>O, resuspended in 1 ml of deionized H<sub>2</sub>O, and placed in a microcentrifuge tube. Samples were pelleted (8k × g for 5 min), resuspended in 500 µl of oxalic acid (20 mM), and stored at 4°C for 16 hours. After incubation, 500 µl of

warm oxalic acid (2 M) was added and 500  $\mu$ l of each sample was transferred to a new amber microfuge tube. The original tubes were transferred to a heat block at 95°C for 30 min, while the new tubes were left at room temperature. Samples were then centrifuged at 16k  $\times$  g for 2 min. 200  $\mu$ l of each sample was transferred to a black 96-well microwell plate and top-read fluorescence measurements were obtained using a Spectramax Gemini EM, with 400 nm excitation light and recording emission intensity at 620 nm. Values of each sample before boiling were subtracted from their boiled counterparts. The resulting values were plotted on a standard curve generated with hemin and are presented in nmols heme/OD<sub>650</sub>. It was formally possible that normalizing heme concentration to OD<sub>650</sub> could alter the ratios between various strains. Comparison of CFUs/OD between strains failed to suggest that the differences in heme levels reported in Table 1 and 2 were not valid (data not shown). Further, assays of representative strains that normalized heme levels to protein detected trends between strains similar to those reported in Table 1 and 2 (data not shown).

### **Aminolevulinic acid synthase (ALAS) activity assays.**

ALAS activity of Hem1p was quantified using a protocol adapted from Whittaker *et. al.* (Whittaker, Penmatsa, & Whittaker, 2015). Reactions consisted of potassium phosphate pH 6.8 (50 mM), L-glycine (100 mM), PLP (10  $\mu$ M) and the relevant protein (~200–1000 nM) in a total volume of 170  $\mu$ l. All components were added and allowed to incubate on a heat block at 30°C for 10 min. When assayed in the presence 3-chloroalanine (3CA), the incubation was at 37°C and 3CA was at 1 mM concentration. The reaction was started with the addition of succinyl-CoA (1 mM final concentration). After incubation for either 30 min (with 3CA) or 1 hour (other assays), the reaction was stopped by addition of 10% TCA. Precipitated protein was removed by centrifugation at 17k  $\times$  g, after which samples were added to 1M sodium acetate (pH 4.6) containing 7.7% v/v acetylacetone. Aminolevulinate in the samples was derivatized by heat treatment (95°C) for 10 min to form a pyrrole. Ehrlich reagent was added and the resulting pyrrole derivative was detected by absorbance at 553 nm. Aminolevulinate present in each sample was determined by interpolating absorbance values onto a standard curve and reported in  $\mu$ mol.

### ***In situ* generation of 2AA and assessment of damage to ALAS.**

A complete reaction contained IlvA (200 nM), Hem1p (1  $\mu$ M) in potassium phosphate pH 8 (50 mM) with NaCl (10 mM). Microfuge tubes containing reaction components were incubated at 30°C for 5 min before adding L-serine (to 100 mM) to start the reaction and bring the total volume to 55  $\mu$ l. The reaction proceeded for 1 hr at 30°C followed by cooling on ice for 5 min. Fifty  $\mu$ l of reaction mix was dispensed onto a 0.025  $\mu$ m MCE membrane filter (MF Millipore VSWP02500) floating on the surface of 25 ml dialysis buffer (KPO<sub>4</sub> pH 8 (50 mM), NaCl (10 mM)) in a petri dish. Dialysis proceeded for approximately one hour in a 4°C cold room, conditions that were empirically determined to eliminate the inhibitory concentration of L-serine. Forty-five  $\mu$ l was removed and transferred into 108  $\mu$ l of ALAS reaction buffer (50 mM potassium phosphate (pH 8), 10 mM NaCl, 170 mM L-glycine) and placed on a heat block at 30°C for 5 min. The ALAS assay was started by the addition of 17  $\mu$ l 10mM succinyl-CoA, bringing the final reaction mix to a total volume of 170  $\mu$ l. ALA was quantified after 60 min.



## RESULTS AND DISCUSSION

### $\rho^+$ *mmf1* mutants of *S. cerevisiae* are compromised in synthesis of aminolevulinic acid.

$\rho^+$  *mmf1* mutants in both YJF153 and S288c strain backgrounds were used to better understand phenotypic consequences of 2AA/2IP accumulation. Two strain backgrounds were used to provide broader insights into enamine/imine stress by identifying if any effects differed between the strains. Genomic differences in YJF153 and S288c did not significantly impact the growth of a *mmf1* yeast in SD. Parental strains YJF153 and S288c reached a similar final OD<sub>650</sub> (0.6 and 0.55 respectively), and the *mmf1* mutation caused a growth defect in both strains (Figure 2). In both cases full growth of the *mmf1* mutant was restored when L-isoleucine was added to the medium. This result was previously reported for the YJF153 strains, where L-isoleucine restored growth by allosterically inhibiting Ilv1p, and preventing the accumulation of 2AA/2IP (D. C. Ernst & Downs, 2018). This behavior is similar to that characterized in *S. enterica* and based on the data in Figure 2, is assumed to extend to the S288c strains.

Growth on Yeast extract Peptone medium containing Dextrose (YPD) was also compromised by a *mmf1* (Figure 2). In this case the *mmf1* strains had a period of slower growth before reaching a growth rate that was similar to the parental strains. Due to the presence of L-isoleucine in YPD, there was little to no 2AA/2IP being generated via Ilv1p. However, the presence of L-serine in YPD induces the expression of *CHA1* and would thus allow 2AA/2IP to be generated. Introduction of *cha1* restored growth of the *mmf1* yeast to that of the parental strains on YPD (data not shown), further supporting a role for 2AA/2IP in causing the growth phenotypes seen.

A culture of a  $\rho^+$  *mmf1* mutant of YJF153 was grown overnight in YP-Glycerol (YPG) and used to seed a soft agar overlay on minimal-glucose (SD) medium. Informed by knowledge of the RidA paradigm in bacteria, forty-nine nutritional supplements were spotted on the surface and stimulation of growth was noted (Table S3). L-Isoleucine stimulated growth likely due to its allosteric inhibition the major producer of 2AA (Ilv1p) and the iron chelator bathophenanthrolinedisulfonic acid (BPS) stimulated growth reflecting the sensitivity of *mmf1* mutants to iron accumulation (D. C. Ernst & Downs, 2018). While a few additional nutrients showed some growth stimulation, the growth allowed by aminolevulinic acid (ALA), an intermediate in the biosynthesis in heme, was noteworthy. ALA is the product of the mitochondrially located PLP-dependent aminolevulinic acid synthase enzyme, Hem1p. Quantification of growth in liquid SD medium showed that exogenous ALA (240  $\mu$ M) had a small but reproducible positive effect on the growth of a  $\rho^+$  *mmf1* mutant of both YJF153 and of S288c (Figure 2).

### Heme biosynthesis is compromised by accumulated 2AA.

Partial restoration of growth by an intermediate in heme biosynthesis (ALA) suggested *mmf1* strains might have lowered heme levels. Isogenic *MMF1* and *mmf1* strains in both the S288c and YJF153 background were grown in different media and total heme content was measured (Table 1). In SD medium, deletion of *mmf1* lowered the heme levels significantly in both S288c and YJF153 strain backgrounds. Mutant derivatives of S288c and

YJF153 had ~60% and ~35% of the heme found in their respective parental strains. When L-isoleucine was present in the growth medium, heme levels in the *mmf1* mutants were restored to those in the respective wildtype. This result implicated 2AA/2IP in generating the lowered heme levels, since exogenous L-isoleucine allosterically inhibits Ilv1p and prevents the formation of these molecules (D. C. Ernst & Downs, 2018). When the growth medium contained ALA (240  $\mu$ M), heme levels in the *mmf1* mutants were restored to ~60–70% of the wild-type levels but notably to the full levels found in the parental strains. The failure of exogenous ALA to fully restore heme levels suggested there was: i) poor transport of ALA, ii) incomplete incorporation of exogenous ALA into the biosynthetic pathway, or iii) an additional bottleneck downstream of Hem1p in heme biosynthesis. A *hem1* mutant of YJF153 was used to distinguish these possibilities. The growth of a *hem1* mutant was restored to near that of wildtype with the addition of 240  $\mu$ M ALA (Figure 3). Thus, growth occurred despite the fact that internal levels of heme reached only ~50% of the wild-type levels in this condition (Table 1). These data suggested that ALA was inefficiently transported and/or incorporated into the biosynthetic pathway. Importantly, the data also showed the level of heme allowed by this ALA supplementation could support wild-type growth. Thus, the minimal growth stimulation achieved by supplementing *mmf1* mutants with ALA showed there were metabolic defects beyond limited heme biosynthesis that impacted growth of the *mmf1* yeast.

A *mmf1* reduced heme levels in YPD medium in addition to SD (Table 1). The presence of L-isoleucine in YPD medium allosterically inhibits Ilv1p, while L-serine in the medium induces expression of *CHAI*. Thus, Cha1p was the presumed source of 2AA/2IP responsible for the reduced heme levels in YPD (D. C. Ernst & Downs, 2018). In this simple scenario, if *CHAI* were eliminated, it would restore heme levels on YPD by preventing 2AA/2IP formation. However, although deleting *CHAI* increased the levels of heme, they were not restored to those of the parental strains (Table 2). This result appeared to eliminate the simple model above. The formal possibility that Ilv1p was not completely inhibited by the level of L-isoleucine in YPD was eliminated since adding L-isoleucine to YPD did not increase heme levels in the *mmf1* strain (data not shown). In total, these data suggested that if 2AA/2IP were responsible for the decreased heme levels in a *mmf1 cha1* yeast in YPD, the source of these metabolites was unknown.

### Specific activity of Hem1p decreases in a *mmf1* mutant.

Hem1p is a fold type I PLP-dependent enzyme that catalyzes the condensation of succinyl-CoA and L-glycine to generate ALA, which is the first committed step of heme biosynthesis and occurs in the mitochondria (Figure 1). The data above raised the possibility that Hem1p was covalently modified by the 2AA/2IP accumulating in the *mmf1* mutant, consistent with the paradigm established for other PLP-enzymes (Borchert et al., 2019). In this scenario and based on precedent in *S. enterica* (Flynn & Downs, 2013; Schmitz & Downs, 2004), the specific activity of Hem1p was predicted to be lower in an *mmf1* yeast compared to the parental *MMF1* strain. The low level of Hem1p in *S. cerevisiae*, in addition to its mitochondrial location and the inability to easily measure expression, complicated further analysis (Gollub, Liu, Dayan, Adlersberg, & Sprinson, 1977). To circumvent these hurdles, the well-characterized *S. enterica ridA* system was used to determine whether yeast



Hem1p was a target of 2AA/2IP *in vivo*. A *S. enterica ridA* mutant (DM17050), and an isogenic wildtype (DM13509) were transformed with pDM1479, which contains *HEM1* expressed by the T7 promoter. Expression of *HEM1* was induced as the wildtype and *ridA* strain grew in minimal glucose medium with added L-serine and L-glycine. L-Serine was added to increase the production of 2AA/2IP, and L-glycine was present to allow growth in the presence of the elevated 2AA/2IP that is present in a *ridA* mutant (Christopherson, Lambrecht, Downs, & Downs, 2012; Dustin C. Ernst & Downs, 2016; Lambrecht et al., 2013). Hem1-His<sub>6</sub> was purified from each strain and ALA synthase specific activity was determined (Figure 4). Hem1p that was purified from the *S. enterica ridA* mutant had 66% the specific activity of the Hem1p that was purified from cells of wildtype ( $8.1 \pm 0.3$  and  $12.3 \pm 0.8$   $\mu\text{mol ALA}/\text{mg ALAS}$ , respectively). These data were consistent with damage to Hem1p by 2AA/2IP in a *ridA* mutant.

Cofactors present in the Hem1p purified from each *S. enterica* strain were extracted and separated by HPLC. If a PLP-dependent enzyme is attacked by 2AA, a pyruvate-PLP adduct that can be released from the enzyme after with treatment by base is generated (Flynn & Downs, 2013; Likos, Ueno, Feldhaus, & Metzler, 1982). The data in Figure 5 showed that a pyruvate-PLP adduct (in addition to PLP) was released from Hem1p purified from a *ridA* mutant background. Significantly, the Hem1p purified from wildtype, where 2AA/2IP does not accumulate, released only the PLP cofactor and had a barely detectable peak where the pyruvate-PLP was expected (Figure 5). Together these data supported the hypothesis that Hem1p is attacked *in vivo* by 2AA/2IP, generating a stably modified enzyme that is inactive.

### Hem1p is damaged by 2AA *in vitro*.

To corroborate the *in vivo* data, Hem1p was purified from *E. coli* strain BL21-AI, which contains wild-type *ridA*, and exposed to 2AA/2IP *in vitro*. Initially, the purified protein was assayed in the presence and absence of 3-chloroalanine (3CA). 3CA reacts with PLP in the active site of some PLP-dependent enzymes, where loss of the chlorine substituent generates 2AA which can damage the active site of target enzymes (Badet, Roise, & Walsh, 1984; Henderson & Johnston, 1976; Relyea, Tate, & Meister, 1974). As such, reaction with 3CA can serve as a predictor of sensitivity to free 2AA or the 2IP tautomer. In the absence of 3CA, Hem1p generated  $26.1 \pm 1.1$   $\mu\text{mol ALA}/\text{mg Hem1p}$  after 30 min, while in the presence of 3CA (1 mM), ALA synthesis dropped to  $7.8 \pm 0.1$  (Figure 6A).

Analysis of direct damage by 2AA/2IP requires that the enamine/imine is generated *in situ* due to the short half-life (3 sec) of these molecules in aqueous solution (Hillebrand, Dye, & Suelter, 1979). Serine dehydratase (IlvA) and cysteine desulfurase (CdsH) have been used to generate 2AA/2IP *in situ* from L-serine or L-cysteine, respectively (D. C. Ernst, Lambrecht, Schomer, & Downs, 2014; Lambrecht et al., 2013). Control reactions showed that Hem1p was inhibited by both L-serine and L-cysteine, complicating the use of these enzymes and requiring that a two-step assay be implemented. Hem1p was incubated with L-serine and serine dehydratase (IlvA) for 60 min to allow generation of 2AA/2IP and time for it to damage Hem1p. Excess L-serine was then removed by filter dialysis before the components needed to assay ALA formation by Hem1p were added. The data are in Figure 6B. When no 2AA was generated in the initial step (i.e., L-serine or IlvA was not present),  $1.4 \pm 0.1$

and  $1.6 \pm 0.1$   $\mu\text{mol ALA/mg ALAS}$  was generated, respectively. In contrast, when both L-serine and IlvA were present to generate 2AA, significantly less activity was detected,  $0.6 \pm 0.2$   $\mu\text{mol ALA/mg ALAS}$ . Finally, when Mmf1p was present in the complete assay, ALAS activity was restored to  $1.9 \pm 0.3$   $\mu\text{mol ALA/mg ALAS}$ . Mmf1p has 2AA/2IP deaminase activity (D. C. Ernst & Downs, 2018), and the restoration of ALAS activity supports the conclusion that Hem1p can be attacked by 2AA/2IP and its activity decreased.

## Conclusions.

Loss of the mitochondrial *ridA* homolog *MMF1* results in numerous phenotypes, which are collectively due to the accumulation of 2AA/2IP in the strain (D. C. Ernst & Downs, 2018). Herein we identify and characterize one target of the accumulated 2AA/2IP as Hem1p, the first enzyme in heme biosynthesis. Our work shows that Hem1p is sensitive to damage by 2AA/2IP *in vivo* and *in vitro*. Further, the data are in support of the conclusion that the reduction of heme levels found in an *mmf1* mutant is at least partially due to damage to Hem1p mediated by 2AA/2IP.

Demonstrating that Hem1p is damaged by 2AA/2IP defines a novel target of enamine/imine damage. The inability of ALA to restore an *mmf1* mutant to full growth on SD showed that Hem1 was not the sole growth determining target of 2AA/2IP in *S. cerevisiae*. Hem1p is the second identified target of 2AA in the yeast mitochondria, with branched chain amino acid transferase (BAT) being the first (D. C. Ernst & Downs, 2018; Kim et al., 2001). Neither the lack of Hem1p or of Bat1p phenocopy the respiratory defects or mtDNA loss associated with a *mmf1* mutant (data not shown). These results suggest multiple small perturbations caused by the accumulation of 2AA/2IP exist in *mmf1* yeast and that they act together to generate phenotypic outcomes. Mitochondrially localized PLP-dependent enzymes are the putative targets for 2AA/2IP in *mmf1* yeast. Several such enzymes are linked directly or indirectly to mitochondrial stability: aspartate amino transferase (EC 2.6.1.1; *AATI*), mitochondrial serine hydroxymethyltransferase (EC 2.1.2.1; *SHMI*), and cysteine desulfurase (EC 2.8.1.7; *NFS1*) (J. Li, Kogan, Knight, Pain, & Dancis, 1999; Luzzati, 1975; Sliwa, Dairou, Camadro, & Santos, 2012). Homologues of *AATI* and *SHMI* are inhibited by 2AA/2IP in *S. enterica* and it is likely their eukaryotic counterparts are also targets of enamine/imines attack (Downs & Ernst, 2015). Continued genetic and biochemical studies will define components of the metabolic network in the mitochondria that are impacted by enamine/imine stress and how they combine to generate the multiple phenotypes of an *mmf1* mutant.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGEMENTS.

The authors would like to thank David Garfinkel for plasmids, technical advice and helpful discussions. This work was supported by an award from the competitive grants program at the NIH (GM095837) to DMD. Authors contributed to; (i) the conception or design of the study (DCE, DMD,GHW), (ii) the acquisition, analysis, or interpretation of the data (GHW, DCE, DMD) and (iii) writing of the manuscript (GHW, DMD).

## DATA AVAILABILITY

The data that supports the findings of this study are within the manuscript or the supplementary material of this article, and additional information is available upon request from the authors.

## REFERENCES

- Ahmed SI, Bollon AP, Rogers SJ, & Magee PT (1976). Purification and properties of threonine deaminase from *Saccharomyces cerevisiae*. *Biochimie*, 58(1–2), 225–232. doi:10.1016/s0300-9084(76)80374-4 [PubMed: 782558]
- Badet B, Roise D, & Walsh CT (1984). Inactivation of the *dadB* *Salmonella typhimurium* alanine racemase by D and L isomers of b-substituted alanines: kinetics, stoichiometry, active site peptide sequencing, and reaction mechanism. *Biochemistry*, 23, 5188–5194. [PubMed: 6439236]
- Borchert AJ, Ernst DC, & Downs DM (2019). Reactive Enamines and Imines In Vivo: Lessons from the RidA Paradigm. *Trends Biochem Sci*, 44(10), 849–860. doi:10.1016/j.tibs.2019.04.011 [PubMed: 31103411]
- Bornaes C, Ignjatovic MW, Schjerling P, Kielland-Brandt MC, & Holmberg S (1993). A regulatory element in the CHA1 promoter which confers inducibility by serine and threonine on *Saccharomyces cerevisiae* genes. *Mol Cell Biol*, 13(12), 7604–7611. doi:10.1128/mcb.13.12.7604 [PubMed: 8246977]
- Christopherson MR, Lambrecht JA, Downs D, & Downs DM (2012). Suppressor analyses identify threonine as a modulator of ridA mutant phenotypes in *Salmonella enterica*. *PLoS ONE*, 7(8), e43082. doi:10.1371/journal.pone.0043082 [PubMed: 22900093]
- Digiovanni S, Visentin C, Degani G, Barbiroli A, Chiara M, Regazzoni L, . . . Popolo L (2020). Two novel fish paralogs provide insights into the Rid family of imine deaminases active in pre-empting enamine/imine metabolic damage. *Sci Rep*, 10(1), 10135. doi:10.1038/s41598-020-66663-w [PubMed: 32576850]
- Downs DM, & Ernst DC (2015). From microbiology to cancer biology: the Rid protein family prevents cellular damage caused by endogenously generated reactive nitrogen species. *Mol Microbiol*, 96(2), 211–219. doi:10.1111/mmi.12945 [PubMed: 25620221]
- ElRamlawy KG, Fujimura T, Baba K, Kim JW, Kawamoto C, Isobe T, . . . Kawamoto S (2016). Der f 34, a Novel Major House Dust Mite Allergen Belonging to a Highly Conserved Rid/YjgF/YER057c/UK114 Family of Imine Deaminases. *J Biol Chem*, 291(41), 21607–21615. doi:10.1074/jbc.M116.728006 [PubMed: 27539850]
- Ernst DC, & Downs DM (2016). 2-Aminoacrylate Stress Induces a Context-Dependent Glycine Requirement in ridA Strains of *Salmonella enterica*. *Journal of Bacteriology*, 198(3), 536–543. doi:10.1128/jb.00804-15 [PubMed: 26574511]
- Ernst DC, & Downs DM (2018). Mmf1p Couples Amino Acid Metabolism to Mitochondrial DNA Maintenance in *Saccharomyces cerevisiae*. *MBio*, 9(1). doi:10.1128/mBio.00084-18
- Ernst DC, Lambrecht JA, Schomer RA, & Downs DM (2014). Endogenous Synthesis of 2-Aminoacrylate Contributes to Cysteine Sensitivity in *Salmonella enterica*. *Journal of Bacteriology*, 196(18), 3335–3342. doi:10.1128/jb.01960-14 [PubMed: 25002544]
- Esaki N, & Walsh CT (1986). Biosynthetic alanine racemase of *Salmonella typhimurium*: purification and characterization of the enzyme encoded by the *alr* gene. *Biochemistry*, 25(11), 3261–3267. [PubMed: 3524677]
- Flynn JM, & Downs DM (2013). In the absence of RidA, endogenous 2-aminoacrylate inactivates alanine racemases by modifying the pyridoxal 5'-phosphate cofactor. *J Bacteriol*, 195(16), 3603–3609. doi:10.1128/JB.00463-13 [PubMed: 23749972]
- Gollub EG, Liu KP, Dayan J, Adlersberg M, & Sprinson DB (1977). Yeast mutants deficient in heme biosynthesis and a heme mutant additionally blocked in cyclization of 2,3-oxidosqualene. *J Biol Chem*, 252(9), 2846–2854. [PubMed: 323256]

- Hans MA, Heinzle E, & Wittmann C (2001). Quantification of intracellular amino acids in batch cultures of *Saccharomyces cerevisiae*. *Appl Microbiol Biotechnol*, 56(5–6), 776–779. [PubMed: 11601629]
- Hegemann JH, & Heck SB (2011). Delete and repeat: a comprehensive toolkit for sequential gene knockout in the budding yeast *Saccharomyces cerevisiae*. *Methods Mol Biol*, 765, 189–206. doi:10.1007/978-1-61779-197-0\_12 [PubMed: 21815094]
- Henderson LL, & Johnston RB (1976). Inhibition studies of the enantiomers of beta chloroalanine on purified alanine racemase from *B. subtilis*. *Biochem Biophys Res Commun*, 68(3), 793–798. [PubMed: 816355]
- Hillebrand GG, Dye JL, & Suelter CH (1979). Formation of an intermediate and its rate of conversion to pyruvate during the tryptophanase-catalyzed degradation of S-o-nitrophenyl-L-cysteine. *Biochemistry*, 18(9), 1751–1755. [PubMed: 435483]
- Hunter S, Jones P, Mitchell A, Apweiler R, Attwood TK, Bateman A, . . . Yong SY (2012). InterPro in 2011: new developments in the family and domain prediction database. *Nucleic Acids Res*, 40(Database issue), D306–312. doi:10.1093/nar/gkr948 [PubMed: 22096229]
- Irons J, Hodge-Hanson KM, & Downs DM (2018). PA5339, a RidA Homolog, Is Required for Full Growth in *Pseudomonas aeruginosa*. *J Bacteriol*, 200(22). doi:10.1128/JB.00434-18
- Irons J, Sacher JC, Szymanski CM, & Downs DM (2019). Cj1388 Is a RidA Homolog and Is Required for Flagella Biosynthesis and/or Function in. *Front Microbiol*, 10, 2058. doi:10.3389/fmicb.2019.02058 [PubMed: 31555246]
- Irons JL, Hodge-Hanson K, & Downs DM (2020). RidA Proteins Protect against Metabolic Damage by Reactive Intermediates. *Microbiol Mol Biol Rev*, 84(3). doi:10.1128/MMBR.00024-20
- Kim JM, Yoshikawa H, & Shirahige K (2001). A member of the YER057c/yjgf/Uk114 family links isoleucine biosynthesis and intact mitochondria maintenance in *Saccharomyces cerevisiae*. *Genes Cells*, 6(6), 507–517. doi:10.1046/j.1365-2443.2001.00443.x [PubMed: 11442631]
- Lambrecht JA, Schmitz GE, & Downs DM (2013). RidA proteins prevent metabolic damage inflicted by PLP-dependent dehydratases in all domains of life. *MBio*, 4(1), e00033–00013. doi:10.1128/mBio.00033-13 [PubMed: 23386433]
- Li J, Kogan M, Knight SA, Pain D, & Dancis A (1999). Yeast mitochondrial protein, Nfs1p, coordinately regulates iron-sulfur cluster proteins, cellular iron uptake, and iron distribution. *J Biol Chem*, 274(46), 33025–33034. doi:10.1074/jbc.274.46.33025 [PubMed: 10551871]
- Li XC, & Fay JC (2017). Cis-Regulatory Divergence in Gene Expression between Two Thermally Divergent Yeast Species. *Genome Biology and Evolution*, 9(5), 1120–1129. doi:10.1093/gbe/evx072 [PubMed: 28431042]
- Likos JJ, Ueno H, Feldhaus RW, & Metzler DE (1982). A novel reaction of the coenzyme of glutamate decarboxylase with L-serine O-sulfate. *Biochemistry*, 21(18), 4377–4386. [PubMed: 6812624]
- Luzzati M (1975). Isolation and properties of a thymidylate-less mutant in *Saccharomyces cerevisiae*. *Eur J Biochem*, 56(2), 533–538. doi:10.1111/j.1432-1033.1975.tb02259.x [PubMed: 1100397]
- Marchler-Bauer A, Zheng C, Chitsaz F, Derbyshire MK, Geer LY, Geer RC, . . . Bryant SH (2013). CDD: conserved domains and protein three-dimensional structure. *Nucleic Acids Res*, 41(Database issue), D348–352. doi:10.1093/nar/gks1243 [PubMed: 23197659]
- Martínez-Chavarría LC, Sagawa J, Irons J, Hinz AK, Lemon A, Graça T, . . . Vadyvaloo V (2020). Putative Horizontally Acquired Genes, Highly Transcribed during *Yersinia pestis* Flea Infection, Are Induced by Hyperosmotic Stress and Function in Aromatic Amino Acid Metabolism. *J Bacteriol*, 202(11). doi:10.1128/JB.00733-19
- Mortimer RK, & Johnston JR (1986). Genealogy of principal strains of the yeast genetic stock center. *Genetics*, 113(1), 35–43. [PubMed: 3519363]
- Niehaus TD, Gerdes S, Hodge-Hanson K, Zhukov A, Cooper AJ, ElBadawi-Sidhu M, . . . Hanson AD (2015). Genomic and experimental evidence for multiple metabolic functions in the RidA/Yjgf/YER057c/UK114 (Rid) protein family. *BMC Genomics*, 16, 382. doi:10.1186/s12864-015-1584-3 [PubMed: 25975565]
- Oxelmark E, Marchini A, Malanchi I, Magherini F, Jaquet L, Hajjibagheri MA, . . . Tommasino M (2000). Mmf1p, a novel yeast mitochondrial protein conserved throughout evolution and involved

in maintenance of the mitochondrial genome. *Mol Cell Biol*, 20(20), 7784–7797. [PubMed: 11003673]

Relyea NM, Tate SS, & Meister A (1974). Affinity labeling of the active center of L-aspartate-beta-decarboxylase with beta-chloro-L-alanine. *J Biol Chem*, 249(5), 1519–1524. [PubMed: 4817757]

Schmitz G, & Downs DM (2004). Reduced Transaminase B (IlvE) Activity Caused by the Lack of *yjgF* Is Dependent on the Status of Threonine Deaminase (IlvA) in *Salmonella enterica* Serovar Typhimurium. *Journal of Bacteriology*, 186(3), 803–810. doi:10.1128/jb.186.3.803-810.2004 [PubMed: 14729707]

Schnackerz KD, Ehrlich JH, Gieseemann W, & Reed TA (1979). Mechanism of action of D-serine dehydratase. Identification of a transient intermediate. *Biochemistry*, 18(16), 3557–3563. doi:10.1021/bi00583a019 [PubMed: 383145]

Sliwa D, Dairou J, Camadro JM, & Santos R (2012). Inactivation of mitochondrial aspartate aminotransferase contributes to the respiratory deficit of yeast frataxin-deficient cells. *Biochem J*, 441(3), 945–953. doi:10.1042/BJ20111574 [PubMed: 22010850]


Walsh C (1982). Suicide substrates: mechanism-based enzyme inactivators. *Tetrahedron*, 38, 871–909.

Whittaker MM, Penmatsa A, & Whittaker JW (2015). The Mtm1p carrier and pyridoxal 5'-phosphate cofactor trafficking in yeast mitochondria. *Arch Biochem Biophys*, 568, 64–70. doi:10.1016/j.abb.2015.01.021 [PubMed: 25637770]

**TAKE AWAYS:**


- *mmf1* yeast accumulate reactive species 2-aminoacrylate and/or 2-iminoaproanoate.
- Imine/enamine accumulation results in low levels of heme in *mmf1* yeast.
- Aminolevulinic acid synthase (Hem1p) is attacked and damaged by 2-aminoacrylate.
- Defective heme biosynthesis is not the cause of all *mmf1* phenotypes.






**Figure 1. Enamine/imine production and the resulting stress in mitochondria.**

2-aminoacrylate (2AA) is generated in yeast mitochondria by PLP-dependent serine/threonine dehydratases Ilv1p and Cha1p (D. C. Ernst & Downs, 2018). *CHA1* is transcribed in the presence of exogenous L-serine or L-threonine and has a role in catabolism of those amino acids. Ilv1p is constitutively synthesized, involved in biosynthesis of L-isoleucine and allosterically inhibited by L-isoleucine. Once formed, 2AA tautomerizes to 2-iminopropionate (2IP) and is ultimately deaminated by solution water, or accelerated by Mmf1p, to pyruvate. In the absence of Mmf1p, 2AA/2IP accumulate *in vivo* to levels sufficient to damage target PLP enzymes. Work herein shows that Hem1p is such a target. Hem1p catalyzes the first committed step in heme biosynthesis, generating 5-aminolevulinic acid in the mitochondria. Subsequent steps in heme synthesis take place in the cytoplasm before the final steps are accomplished in the mitochondrion, as schematically represented. Past work demonstrated that branched chain amino acid transaminase is also a target for damage by 2AA/2IP (D. C. Ernst & Downs, 2018). The relevant pathways are schematically shown in the figure; red lines indicate points of post translational inhibition, yellow hexagons depict PLP cofactors and the biosynthetic steps to heme are depicted where they occur, either internal, or external to the mitochondrion. Both Ilv1p and Cha1p act on L-threonine and via enamine/imine formation generate the  $\alpha$ -ketobutyrate that is an intermediate in the biosynthesis of L-isoleucine.




**Figure 2. Growth of *mmf1* strains is compromised.**

YJF153, S288c and *mmf1* derivatives of these strains were grown on SD medium (panel A,B) or YPD (panel C). Growth was monitored as the OD<sub>650</sub> over time. SD medium was supplemented with 5-aminolevulinic acid (ALA, 240  $\mu$ M), or L-isoleucine (Ile, 1 mM) as indicated. The data represent the average and standard error of three biological replicates.




**Figure 3. 5-aminolevulinic acid restores growth of a *hem1* mutant.**

Growth of a YJF153 parent and *hem1* mutant strain was monitored in SD media with or without the addition of 5-aminolevulinic acid (ALA) as indicated.




**Figure 4. Hem1p specific activity is affected by genetic background.**

Hem1p was purified from either the wildtype (WT) or a *ridA* mutant strain of *Salmonella enterica* as indicated on the X axis. The purified protein was assayed for ALAS activity and the specific activity reported in μmol ALA/mg ALAS. The data shown are averages of triplicate technical replicates and significance (indicated by asterisk) was confirmed when a P value of 0.0042 was determined with an unpaired t test. Data are from a representative experiment that was repeated twice with two independent biological samples.



**Figure 5. Pyruvate-PLP is released from Hem1p after synthesis in a *ridA* mutant.** Hem1p was purified from two *S. enterica* strains; wildtype (solid lines) and a *ridA* mutant (dashed lines). Cofactors were released from the protein by treatment with base and separated with HPLC, while monitored by absorbance at 305 nm. The peak eluting with a retention time of ~7.4 min was PLP and the one at ~9.5 min was pyruvate-PLP. Peak assignment was based on retention time, UV-Vis spectra, and co-injection with authentic compounds (Figure S3).



**Figure 6. Hem1p is sensitive to 2AA *in vitro*.**

Hem1p was expressed and purified from BL21 *E. coli* and assayed for activity under multiple conditions. **(A)** Hem1p was incubated with 3-chloroalanine (3CA) prior to assaying ALA synthesis. Data are representative averages of three technical replicates. The difference is significant as determined by unpaired t test ( $P < .0001$ ). **(B)** ALAS activity of Hem1p was determined after exposure to the 2AA/2IP generated *in situ* by IlvA as described in Materials and Methods. Components present in the preincubation stage of the protocol are indicated below the Y axis. Data shown are representative of at least 2 independent experiments. Each condition consisted of 4 technical replicates with significance determined by one way ANOVA. \* indicates P value  $< .001$ .



**Table 1.**

An *mmf1* mutant has decreased heme levels.

		Heme levels <sup>a</sup>			
		Medium			
Strain	Genotype	SD	SD + Ile	SD + ALA	YPD
YJF153	YJF153	254 ± 29	238 ± 10	251 ± 26	258 ± 26
Dmy41	YJF153 <i>mmf1</i>	90 ± 10	241 ± 13	157 ± 13	80 ± 7
Dmy74	YJF153 <i>hem1</i>	ND	ND	124 ± 26	ND
Dmy61	S288c	140 ± 25	186 ± 39	176 ± 12	217 ± 8
Dmy67	S288c <i>mmf1</i>	84 ± 8	176 ± 19	125 ± 4	65 ± 9

Mutants lacking *MMF* or *HEM1* in each of two strain backgrounds (YJF153 and S288c) were grown in the indicated medium. When added, L-isoleucine and aminolevulinic acid were at 1 mM and 240 μM, respectively. Data are from a representative experiment with three biological replicates and reported as average plus or minus 1 standard deviation. Abbreviations: SD, synthetic dextrose; YPD, yeast peptone dextrose; Ile, L-isoleucine; ALA, aminolevulinic acid.; ND, not determined.

<sup>a</sup>Heme levels were measured as described in Materials and Methods and are reported in pmol/OD<sub>650</sub>.

**Table 2.**

Cha1p contributes to the decreased heme levels of an *mmf1* mutant on YPD.

Strain	Genotype	Heme levels <sup>a</sup>
YJF153	YJF153	206 ± 26
Dmy41	YJF153 <i>mmf1</i>	64 ± 24
Dmy16	YJF153 <i>cha1</i>	216 ± 21
Dmy20	YJF153 <i>mmf1 cha1</i>	96 ± 9
Dmy61	S288c	209 ± 4
Dmy67	S288c <i>mmf1</i>	69 ± 10
Dmy111	S288c <i>mmf1 cha1</i>	133 ± 16

Mutants lacking *MMF1* and/or *CHA1* in two strain backgrounds (YJF153 and S288c) were grown in YPD medium. Data are from a representative experiment with 4 biological replicates and reported as average plus or minus 1 standard deviation.

<sup>a</sup>Heme levels were measured as described in Materials and Methods and are reported in pmol/OD<sub>650</sub>.